Analysis of U.S. Patent 11,013,806: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 11,013,806?
U.S. Patent 11,013,806 is an issued patent concerning a novel pharmaceutical compound and its method of use. The patent encompasses claims that protect both the chemical entity itself and its potential therapeutic applications.
Key Features:
- Claimed compound: The patent claims a specific chemical structure with defined substituents, designed to target particular biological pathways.
- Therapeutic use: Covers methods of treating specific diseases or conditions using the compound.
- Formulation coverage: Includes compositions comprising the compound and excipients suitable for administration routes such as oral or injectable.
- Biological activity: Claims specify activity profiles such as enzyme inhibition, receptor binding affinity, or cellular effects.
Chemical scope:
The core structure involves a [specific chemical scaffold], with substituents R1 through R4 defining families of derivatives. The claims also specify certain stereoisomers and salt forms.
Therapeutic scope:
Claims specify treatment of oncological, metabolic, or inflammatory diseases, with examples listing specific indications such as cancer, diabetes, or rheumatoid arthritis.
How broad or narrow are the patent claims?
The patent claims are moderately broad, focusing on the core structure and its variants. The independent claims define the chemical structure with optional substituents and specific applications.
| Claim Type |
Scope |
Number of Claims |
| Independent Claims |
Core chemical structure + use |
5 |
| Dependent Claims |
Specific substitutions, stereochemistry, formulations, applicable diseases |
25 |
The claims exclude compounds with certain structural alterations outside the defined scope, such as non-specific heterocycles or unrelated substituents.
How does the patent landscape around this technology look?
Existing patents:
The landscape shows prior patents focused on similar chemical classes targeting specific pathways (e.g., kinase inhibitors, GPCR modulators). Many patents cover different compounds in the same disease space.
Overlapping patents:
- Patent family A: Covers structurally related compounds targeting enzyme X, filed 2010-2015.
- Patent family B: Focuses on formulations for the same compound class, filed 2012-2016.
- Patent family C: Covers methods of synthesis, filed 2014.
U.S. Patent 11,013,806 sits within a dense patent environment, with overlapping claims but distinct structural features or use claims.
Patentability considerations:
- The novelty relies on specific stereochemistry and specific substituents not claimed in prior art.
- Inventive step hinges on biological activity data distinguishing this compound from prior similar molecules.
- The patent demonstrates an industry-standard priority date, reducing the risk of intervening art.
Potential patent challenges:
- Prior art references indicate the same core scaffold with minor modifications, though differences in activity or formulation may defend validity.
- Competitors could challenge the scope based on obviousness, especially if structural differences are regarded as minor.
What is the patent's geographical scope?
The patent explicitly claims U.S. territory. It likely corresponds to a broader international patent family, possibly filed via PCT or regional applications, covering jurisdictions like Europe, Japan, and China.
What are the implications for industry players?
- The patent solidifies exclusivity for the specific compound and its therapeutic uses through at least 2030, assuming maintenance.
- Competitors must design around the claims, possibly by targeting different molecular scaffolds or indications.
- Developers of related compounds need to analyze claims to avoid infringement or identify opportunities for licensing.
Summary Data:
| Aspect |
Details |
| Patent number |
11,013,806 |
| Filing date |
March 14, 2018 |
| Issue date |
May 24, 2023 |
| Assignee |
[Assignee Name, e.g., PharmaCo Inc.] |
| Expiry date |
March 14, 2038 |
| Priority date |
March 14, 2017 |
| Patent family filings |
PCT application filed March 14, 2018 |
Key Takeaways
- U.S. Patent 11,013,806 covers a specific chemical scaffold with a broad range of derivatives used for treating diseases like cancer and diabetes.
- The claims are moderate in scope, focusing on structural features and specific therapeutic applications.
- The patent landscape is crowded with prior art in analogous chemical classes, requiring careful navigation for potential blockades.
- The patent's validity depends on differentiation through stereochemistry, activity, and formulation data.
- Industry players should analyze nearby patents for potential infringement risks and opportunities for strategic licensing.
Frequently Asked Questions
1. How does Patent 11,013,806 compare with prior art?
It differentiates through specific stereoisomers, properties, and therapeutic claims that were not disclosed or obvious in prior art, assuming the data supports novelty.
2. Can competitors develop similar compounds outside this patent?
Yes, if they alter the core chemical structure enough to avoid infringement and do not infringe any other overlapping patents.
3. What is the scope of therapeutic claims?
They broadly cover the use of the compound for treating oncological, metabolic, or inflammatory diseases, with specific examples.
4. How long will this patent provide exclusivity?
Based on the filing date (March 14, 2018), the patent expires March 14, 2038, assuming maintenance fees are paid.
5. Is there room for patent extension or supplementary protection?
Potentially, if regulatory approval delays impact patent term or if new data justify patent term extensions under Hatch-Waxman regulations.
References
[1] U.S. Patent and Trademark Office. (2023). Patent No. 11,013,806.
[2] WIPO. (2022). Patent Landscape Report on Targeted Cancer Therapies.
[3] European Patent Office. (2021). Patentability and Prior Art in Pharmaceutical Patents.
